Integrated Filing — IndAS



General information about company

Scrip Code 524470
NSE Symbol SYNCOMF
MSEI Symbol NOTLISTED
ISIN INE312C01025
Name of company SYNCOM FORMULATIONS INDIA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 11-08-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 06-08-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 11-08-2026   16:00:00
End date and time of board meeting 11-08-2026   16:45:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 12,552.64 12,552.64
Other income 782.94 782.94
Total income 13,335.58 13,335.58
2 Expenses
(a) Cost of materials consumed 5,877.62 5,877.62
(b) Purchases of stock-in-trade 1,824.49 1,824.49
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (1,115.72) (1,115.72)
(d) Employee benefit expense 1,716.67 1,716.67
(e) Finance costs 24.45 24.45
(f) Depreciation, depletion and amortisation expense 154.03 154.03
(f) Other Expenses
1 Others 1,628.82 1,628.82
Total other expenses 1,628.82 1,628.82
Total expenses 10,110.36 10,110.36
3 Total profit before exceptional items and tax 3,225.22 3,225.22
4 Exceptional items 0.00 0.00
5 Total profit before tax 3,225.22 3,225.22
6 Tax expense
7 Current tax 727.65 727.65
8 Deferred tax 12.89 12.89
9 Total tax expenses 740.54 740.54
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 2,484.68 2,484.68
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 2,484.68 2,484.68
17 Other comprehensive income net of taxes 381.87 381.87
18 Total Comprehensive Income for the period 2,866.55 2,866.55
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 0.00 0.00
Total profit or loss, attributable to non-controlling interests 0.00 0.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 0.00 0.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0.00 0.00
21 Details of equity share capital
Paid-up equity share capital 9,400.00 9,400.00
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.26 0.26
Diluted earnings (loss) per share from continuing operations 0.26 0.26
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.26 0.26
Diluted earnings (loss) per share from continuing and discontinued operations 0.26 0.26
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026 01-04-2026
Date of end of reporting period 30-06-2026 30-06-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Pharmaceuticals Drugs & formulations 13,223.61 13,223.61
2 Trading of Commodities 0.0002784 0.0002784
3 Renting of Property 0.0008413 0.0008413
Total Segment Revenue 13,335.58 13,335.58
Less: Inter segment revenue 0.00 0.00
Revenue from operations 13,335.58 13,335.58
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Pharmaceuticals Drugs & formulations 3,170.25 3,170.25
2 Trading of Commodities 1.99 1.99
3 Renting of Property 77.43 77.43
Total Profit before tax 3,249.67 3,249.67
i. Finance cost 24.45 24.45
ii. Other Unallocable Expenditure net off Unallocable income 0.00 0.00
Profit before tax 3,225.22 3,225.22
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Pharmaceuticals Drugs & formulations 46,037.15 46,037.15
2 Trading of Commodities 4.56 4.56
3 Renting of Property 9,257.24 9,257.24
Total Segment Asset 55,298.95 55,298.95
Un-allocable Assets 0.00 0.00
Net Segment Asset 55,298.95 55,298.95
4 Segment Liabilities
Segment Liabilities
1 Pharmaceuticals Drugs & formulations 10,789.14 10,789.14
2 Trading of Commodities 12.50 12.50
3 Renting of Property 284.16 284.16
Total Segment Liabilities 11,085.80 11,085.80
Un-allocable Liabilities 0.00 0.00
Net Segment Liabilities 11,085.80 11,085.80
Disclosure of notes on segments Textual Information(2)



Text Block

Textual Information(2) 1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 11.08.2026 2 These above results have been prepared in compliance with the Indian Accounting Standard referred to as Ind AS as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies Indian Accounting Standards Rules 2015 as amended from time to time. 3 The company is operating in 3 segments i.e. a Pharmaceuticals Drugs & Formulations b Trading of Commodities c Renting of Property, particulars of segment wise results are given as required. 4 As required under Regulation 33 of SEBI LODR Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th June, 2026. The report does not have any impact on the above results and notes which needs explanation. 5 The Company currently have 3 Three Wholly owned Subsidiaries namely Synmex Pharma Pvt Ltd , Vincit Pharma Pvt Limited and Sante Biotech Pvt Ltd 6 During the current period, the Company has corrected its method of calculating Earnings Per Share EPS. In previous years/Quarters, EPS was calculated considering Total Comprehensive Income. To comply with the requirements of Ind AS 33, the EPS has now been computed using Profit After Tax attributable to equity shareholders. Consequently, the comparative EPS for all preceding periods has been restated. There is no restatement in any line items only EPS is restated. The Figurs as Previously reported and restated are as below Previously Reported EPS TCI Quarter Ended Year Ended 30-06-2026 31-03-2026 30-06-2025 31-03-2026 Unaudited Audited Unaudited Audited Earnings per equity share for discontinued & continuing operations (1) Basic NA NA 0.21 NA (2) Diluted NA NA 0.21 NA Restated EPS PAT Earnings per equity share for discontinued & continuing operations (1) Basic 0.26 0.27 0.17 0.81 (2) Diluted 0.26 0.27 0.17 0.81



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
1 Item that will be reclassified to profit and loss 381.87 381.87
Total Amount of items that will be reclassified to profit and loss 381.87
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 381.87 381.87